Article

Daily Medication Pearl: Piperacillin and Tazobactam (Zosyn)

Piperacillin and tazobactam (Zosyn) is indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.

Medication Pearl of the Day: Piperacillin and Tazobactam (Zosyn)

Indication: Piperacillin and tazobactam (Zosyn) is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of intra-abdominal infections, skin and skin structure infections, female pelvic infections, community-acquired pneumonia, and nosocomial pneumonia.

Insight:

  • Dosing: The usual daily dose of Zosyn for adults is 3.375 g every 6 hours, totaling 13.5 g.
  • Dosage forms: Zosyn for injection 2.25 g, 3.375 g, and 4.5 g lyophilized powder for reconstitution in single-dose vials and 40.5 g lyophilized powder for reconstitution in pharmacy bulk vials.
  • Adverse events: The most common adverse reactions (incidence >5%) are diarrhea, constipation, nausea, headache, and insomnia.
  • Mechanism of action: Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria. In vitro, piperacillin is active against a variety of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Tazobactam sodium has little clinically relevant in vitro activity against bacteria due to its reduced affinity to penicillin-binding proteins.

Source: ZOSYN (piperacillin and tazobactam) for injection (fda.gov)

Related Videos
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Pharmacists working in a pharmacy -- Image credit: Drazen | stock.adobe.com
Image Credit: © Krakenimages.com - stock.adobe.com
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC